- Asia
- Automobile
- Bangladesh
- Banking
- Biological Inventions
- bLAWgathon
- Brand Valuation
- Business
- Company Law
- Competition Law
- Constitutional Law
- Consumer Law
- Copyright
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Counterfeiting
- Covid
- Design
- Digital Media
- Digital Right Management
- Educational Conferences/ Seminar
- Fashion Law
- GDPR
- GIg Economy
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- IBC
- India
- Indonesia
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Khadi Industries
- labour Law
- Legal Issues
- Licensing
- Media & Entertainment Law
- Myanmar
- NCLT
- NEPAL
- News & Updates
- Online Gaming
- Patent Act
- Patent Commercialisation
- Patent Fess
- Patent Filing
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent Rule Amendment
- Patents
- pharma
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Pollution
- Protection of SMEs
- Section 3(D)
- Signapore
- Social Media
- Sports Law
- Stock Exchange
- TAX
- Technology
- Telecom Law
- Telecommunications
- Thailand
- Trademark
- Trademark Infringement
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
The Nagoya Protocol – Convention on Biological Diversity
21st July, 2014 - 9:10 am
Categories:
News & Updates
Patent Commercialisation
Patents
Pharma- biotech- Patent Commercialisation
0 Comments
A new international treaty named the “Nagoya Protocol” will be giving some relief to India and other developing countries. The Nagoya Protocol on Access to Genetic Resources with an objective of ensuring access of genetic resources to the signatory countries and ensuring fair and equitable sharing of benefit to the local community and signatory country that … Continue reading The Nagoya Protocol – Convention on Biological Diversity
Read more »Anti Cancer drug: Making it Patient-driven, not Disease-driven
11th April, 2011 - 10:16 am
Categories:
Patent Commercialisation
Pharma- biotech- Patent Commercialisation
0 Comments
Introduction: French compatriots Ipsen and bioMérieux, have been few most potential companies, since 2007 in the development of companion assay to assess patient benefit from a compound useful for treating several severe forms of cancers.Partnership between two companies has focused on the two main broad areas of pharma research: Personalized medicine and Theronostics. Personalized medicine … Continue reading Anti Cancer drug: Making it Patient-driven, not Disease-driven
Read more »Roche’s Struggle Over its Patents in India – Two suits, Two oppositions
27th July, 2010 - 4:47 am
Categories:
Patent Litigation
Pharma/Biotech Patent Litigations
2 Comments
The struggle between innovator pharmaceutical companies (mostly in the Western world) and developing world Generic companies has been lately played out in India and especially for the last 2-3 years in the form of litigations and oppositions. Here I would be discussing the specific case of Roche (a Swiss Pharma Company) showcasing its journey of … Continue reading Roche’s Struggle Over its Patents in India – Two suits, Two oppositions
Read more »